By way of Ameet Sarpatwari, Aviva Wang, and Aaron S. Kesselheim
Every month, participants of the Program On Law, Therapeutics, And Legislation (PORTAL) evaluation the peer-reviewed scientific literature to spot attention-grabbing empirical research, coverage analyses, and editorials on well being legislation and coverage problems.
Underneath are the citations for papers known from the month of April. The choices characteristic subjects starting from an research of presidency and trade investments for lately authorized medicine, to a dialogue of courtroom selections on mifepristone, and an exam of the added healing get advantages related to the top-selling brand-name medicine in Medicare.
A complete posting of abstracts/summaries of those articles could also be discovered on our website online.
- Galkina Cleary E, Jackson MJ, Zhou EW, Ledley FD. Comparability of Analysis Spending on New Drug Approvals by way of the Nationwide Institutes of Well being vs the Pharmaceutical Business, 2010-2019. JAMA Well being Discussion board. 2023 Apr 7;4(4):e230511. (PMID: 37115539).
- Aaron DG, Brown TR, Sinha MS. Court docket Intrusion Into Science and Medication-the Mifepristone Selections. JAMA. 2023 Apr 26. [Epub ahead of print]. (PMID: 37099527).
- Avorn J. Surrogate Measures of Drug Efficacy-A Finger Pointing on the Moon. JAMA Netw Open. 2023 Apr 3;6(4):e238835. (PMID: 37115553).
- Cliff ERS, Kesselheim AS, Rome BN, Feldman WB. Developments in Medicare Spending on Oral Medication for Persistent Lymphocytic Leukemia From 2014 to 2020. JAMA Netw Open. 2023 Apr 3;6(4):e237467. (PMID: 37027159).
- Egilman AC, Rome BN, Kesselheim AS. Added Healing Good thing about Best-Promoting Logo-name Medication in Medicare. JAMA. 2023 Apr 18;329(15):1283-1289. (PMID: 37071095).
- Essa M, Ross JS, Dhruva SS, Desai NR, Yeh RW, Faridi KF. Developments in Spending and Claims for P2Y12 Inhibitors by way of Medicare and Medicaid From 2015 to 2020. J Am Center Assoc. 2023 Apr 18;12(8):e028869. [Epub 2023 Apr 12]. (PMID: 37042289).
- Hamburg M, Sharfstein J. Judicial Interference with Mifepristone. Science. 2023 Apr 21;380(6642):223. [Epub 2023 Apr 13]. (PMID: 37053463).
- McPhail M, Zhang H, Bhimani Z, Bubela T. Classes from Canada’s Realize of Compliance with Prerequisites Coverage for the Lifestyles-Cycle Law of Medication. J Legislation Biosci. 2023 Apr 12;10(1):lsad008. (PMID: 37064046).
- Olivier T, Haslam A, Prasad V. Is Monetary Toxicity Captured in High quality of Lifestyles Checks in Oncology Randomized Medical Trials? J Most cancers Coverage. 2023 Apr 17;36:100423. [Epub ahead of print]. (PMID: 37075841).
- Rome BN, Kesselheim AS. Biosimilar Festival for Humira is Right here: Indicators of Hope Regardless of Early Hiccups. Arthritis Rheumatol. 2023 Apr 7. [Epub ahead of print]. (PMID: 37026489).
The submit Per month Spherical-Up of What to Learn on Pharma Legislation and Coverage gave the impression first on Invoice of Well being.
